Skip to Content

China Resources Pharmaceutical Group Ltd Registered Shs Unitary 144A/Reg S 03320

Morningstar Rating
HKD 5.75 +0.04 (0.70%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

China Resources Pharmaceutical Group Is the Third-Largest Medical Distributor in China

The revenue of China Resources Pharmaceutical Group grew at a compounded annual growth rate of 10.4% over the past 10 years. The growth is driven by its medical distribution segment due to industry consolidation and industry expansion. Similar to other larger pharmaceutical distributors, CR Pharma, in our view, is likely to grow faster than the distribution industry average in the next three years as the industry consolidates further.

Price vs Fair Value

03320 is trading at a 346% premium.
Price
HKD 5.71
Fair Value
HKD 2.91
Uncertainty
High
1-Star Price
HKD 6.43
5-Star Price
HKD 3.26
Economic Moat
Sgwlg
Capital Allocation
Gjkcmgpd

Bulls Say, Bears Say

Bulls

Price cuts for volume-based procurement are more lenient, raising CR Pharma’s operating margin.

Bears

The current cycle of interest-rate cuts in China reverses, leading to higher short-term interest servicing costs for CR Pharma.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 03320 is a good fit for your portfolio.

Trading Information

Previous Close Price
HKD 5.71
Day Range
HKD 5.605.76
52-Week Range
HKD 4.456.56
Bid/Ask
HKD 5.74 / HKD 5.75
Market Cap
HKD 36.12 Bil
Volume/Avg
5.4 Mil / 9.4 Mil

Key Statistics

Price/Earnings (Normalized)
6.83
Price/Sales
0.13
Dividend Yield (Trailing)
2.97%
Dividend Yield (Forward)
2.97%
Total Yield
4.57%

Company Profile

China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2023, the medical distribution business accounts for 82.6% of its total revenue. CR Pharma’s manufacturing business, 17.8% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Value
Total Number of Employees
72,986

Competitors

Valuation

Metric
03320
COR
01099
Price/Earnings (Normalized)
6.8317.326.71
Price/Book Value
0.7140.990.79
Price/Sales
0.130.160.10
Price/Cash Flow
2.8713.833.27
Price/Earnings
03320
COR
01099

Financial Strength

Metric
03320
COR
01099
Quick Ratio
1.000.501.05
Current Ratio
1.330.891.39
Interest Coverage
4.899.107.35
Quick Ratio
03320
COR
01099

Profitability

Metric
03320
COR
01099
Return on Assets (Normalized)
3.90%4.19%4.43%
Return on Equity (Normalized)
20.49%373.63%24.34%
Return on Invested Capital (Normalized)
7.28%47.73%9.74%
Return on Assets
03320
COR
01099
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
MbjcvnbwqkSmv$79.8 Bil
Merck KGaA ADR
MKKGY
GqlgrnnlYvlnr$71.7 Bil
Haleon PLC ADR
HLN
ZmffkkmFqxq$37.9 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
CyjfyrmDgv$13.0 Bil
Viatris Inc
VTRS
GjrxtvdrpPtttz$12.3 Bil
Catalent Inc
CTLT
LbcchxghFgxwxp$10.3 Bil
Perrigo Co PLC
PRGO
VkbwhrnvBkbrq$3.5 Bil
Prestige Consumer Healthcare Inc
PBH
BfbnjjztvYzjpp$3.4 Bil
Curaleaf Holdings Inc
CURLF
QykpmpvzTklv$2.8 Bil
Green Thumb Industries Inc
GTBIF
TjkdhrhbbZqbt$2.7 Bil

Sponsor Center